Complex therapy of heart failure in newborns with congenital heart diseases by preparations of metabolic action

Among diseases of the cardiovascular system in infants, congenital heart and vascular defects occupy a dominant place. The birth of children with congenital heart disease is a serious problem due to the risk of infant mortality. The development of heart failure in congenital heart defects is an uncommon syndrome complex that requires the use of complex drug therapy. In the course of our study, we evaluated the results of the use of complex medical therapy for heart failure in newborns. We found that drug therapy in newborns with congenital heart defects using cardiometabolic agents reliably improves intracardiac hemodynamics - the size of the right heart cavities decreases, the ejection fraction increases, the metabolic process improves, and the child's overall condition and well-being improves. Thus, newborns with congenital heart defects need not only cardiotonic but also cardiotrophic therapy.